Q3 FY26Published 06 Feb 2026Call held 06 Feb 2026
SHILPAMED Q3 FY26 Earnings Call Transcript & Analysis
Revenue₹411 cr+28% YoYEBITDA₹115 cr+41% YoYEBITDA Margin28%+2% YoYPAT₹55 crAdjusted ROCE17%
Revenue ₹411 cr (+28% YoY); EBITDA ₹115 cr (+41% YoY); EBITDA Margin 28% (+2% YoY). Revenue of ₹411 crores, up 28% YoY.
Read full transcript & analysis